Key result
BNT162b2 mRNA vaccination linked to spontaneously resolving transient pneumonitis in a rheumatoid arthritis patient.
Why the study?
Some patients develop late hypersensitivity autoimmune reactions after COVID-19 vaccination, prompting reporting of rare events such as pneumonitis.
Case Report (n=1)
Highlights a possible rare adverse reaction of transient pneumonitis following COVID-19 mRNA vaccination in a patient with rheumatoid arthritis.
May warrant vigilance for rare pneumonitis in vaccinated RA patients; hypothesis-generating and requires confirmation in larger cohorts.
The coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 has led to rapid progress in vaccine development to prevent the spread of the disease. Although COVID-19 vaccines have excellent effectiveness in reducing morbidity and disease severity with minor adverse reactions, some patients develop late hypersensitivity events as autoimmune reactions such as rheumatoid arthritis, lupus nephritis, and vasculitis following COVID-19 vaccination. Herein, we describe a case of pneumonitis following COVID-19 mRNA vaccination in a patient with rheumatoid arthritis, which resolved spontaneously.
No takes yet. Share an insight, caveat, or question.
Ohkubo et al. (2022) conducted a case report in Rheumatoid arthritis (n=1). BNT162b2 COVID-19 mRNA Vaccine was evaluated on Development of pneumonitis. BNT162b2 COVID-19 mRNA vaccination was associated with transient pneumonitis in a patient with rheumatoid arthritis, which resolved spontaneously.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: